Rosetta Genomics (NASDAQ: ROSG) and Crispr Therapeutics (NASDAQ:CRSP) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk. Insider & Institutional Ownership 7.5% of Rosetta Genomics shares are held by institutional investors. […]

Animal and plant breeders are trying out a set of powerful new tools which have the potential to revolutionize agricultural practices and provide consumers with more healthy and safe food options. Their new toolbox is called gene editing, and the instruments in it have strange-looking names: endonucleases, for example, which are enzymes breeders can use […]

Authors: Poornima Ramkumar, Martin Kampmann Abstract The future of cancer precision medicine lies in the rational design of effective therapies tailored to each patient based on the genetic makeup of their tumor. While the investigation of cancer genomes has successfully revealed cancer driver genes, leading to the development of targeted therapies, drug resistance is a […]

Medtronic plc (NYSE:MDT) has a price-to-sales ratio of 3.91, well below its Medical Appliances & Equipment competitors. For the industry, the average P/S ratio sits at 7.6, which is more than the sector’s 6.56. In the past 13-year record, this ratio went down as low as 1.92 and as high as 5.25. Also, it is […]

January 15, 2018 – By Nellie Frank The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) reached all time high today, Jan, 15 and still has $30.23 target or 6.00% above today’s $28.52 share price. This indicates more upside for the $1.17B company. This technical setup was reported by If the $30.23 PT is reached, the […]

NEW YORK (GenomeWeb) – Desktop Genetics announced today that it has acquired an exclusive license to technology for the assessment of genome-editing efficacy from the Netherlands Cancer Institute (NKI). Under the terms of the deal, London-based Desktop will have the exclusive global rights to TIDE — short for tracking of indels by decomposition — a […]

January 15, 2018 – By Marguerite Chambers Among 11 analysts covering Abraxas Petroleum (NASDAQ:AXAS), 9 have Buy rating, 0 Sell and 2 Hold. Therefore 82% are positive. Abraxas Petroleum had 30 analyst reports since July 21, 2015 according to SRatingsIntel. On Wednesday, July 13 the stock rating was initiated by Ladenburg Thalmann with “Buy”. The […]

The ever-expanding limits of human reproduction are creating complex ethical and political challenges. One topic that has generated much contention is the possibility of editing the genome of human embryos. The fourth session of the Progress Educational Trust (PET)’s Annual Conference ‘Crossing Frontiers: Moving the Boundaries of Human Reproduction‘ focused on the current status of […]

Investors are constantly examining different company financial indicators to assess trading opportunities. CRISPR Therapeutics AG (NasdaqGM:CRSP) presently has an EV or Enterprise Value of 1074458. The EV is used to show how the market assigns value to a company as a whole. EV is basically a modification of market cap, as it incorporates debt and […]

The human adaptive immune response against the Cas9 protein – part of the CRISPR/Cas9 genome editing system – may pose a barrier to new therapies, suggests a new study. ‘This was a fully expected observation, since we are all constantly exposed to many microbes,’ Professor George Church, a geneticist at Harvard Medical School, who was […]